Inactive Instrument

Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Biotechnology & Medical Research

Intercept Pharmaceuticals, Inc. Announces Resignation of Ryan T. Sullivan as General Counsel and Secretary, Effective December 11, 2020

November 17, 2020 at 04:09 pm EST

On November 12, 2020, Ryan T. Sullivan notified Intercept Pharmaceuticals, Inc. of his decision to resign from his position as the Company's General Counsel and Secretary, effective December 11, 2020, in order to pursue other opportunities. Mr. Sullivan's resignation was not the result of any disagreement regarding any matter related to the Company's operations, policies or practices.

Latest news about Intercept Pharmaceuticals, Inc.

North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023	Nov. 13	CI
Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023	Nov. 10	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Composite Index	Nov. 08	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P TMI Index	Nov. 08	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Global BMI Index	Nov. 08	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Biotechnology Select Industry Index	Nov. 08	CI
Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc..	Nov. 07	CI
North American Morning Briefing : Higher Bond -2-	Nov. 07	DJ
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Biotechnology Index	Nov. 07	CI
Intercept Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors	23-10-23	CI
North American Morning Briefing : Rising Oil -2-	23-09-28	DJ
UBS Raises Intercept Pharmaceuticals Price Target to $19 From $12, Maintains Neutral Rating	23-09-27	MT
HC Wainwright Downgrades Intercept Pharmaceuticals to Neutral From Buy, Price Target is $19	23-09-27	MT
Canaccord Genuity Downgrades Intercept Pharmaceuticals to Hold From Buy, Trims Price Target to $19 From $20	23-09-27	MT
RBC Raises Price Target on Intercept Pharmaceuticals to $19 From $12 on Deal to Be Bought by Alfasigma; Sector Perform Kept	23-09-27	MT
B. Riley Downgrades Intercept Pharmaceuticals to Neutral From Buy After Announced Sale to Alfasigma, Lifts PT to $19 From $15	23-09-27	MT
Sector Update: Health Care Stocks Lower Late Tuesday Afternoon	23-09-26	MT
Sector Update: Health Care Stocks Declining in Afternoon Trading	23-09-26	MT
Intercept Pharmaceuticals Agrees to be Acquired by Alfasigma for $19 Per Share; Stock Soars Pre-Bell	23-09-26	MT
Italy's Alfasigma to buy drugmaker Intercept for nearly $800 mln	23-09-26	RE
UBS Adjusts Intercept Pharmaceuticals Price Target to $12 From $20, Maintains Neutral Rating	23-08-14	MT
Transcript : Intercept Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 02, 2023	23-08-02
Earnings Flash (ICPT) INTERCEPT PHARMACEUTICALS Reports Q2 Revenue $83.7M, vs. Street Est of $79.6M	23-08-02	MT

Chart Intercept Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company's marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.

Sector

Biotechnology & Medical Research

Calendar

2024-05-18 - Digestive Disease Week Conference - Abstract No #155

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	111B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.58%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.54B
LEGEND BIOTECH CORPORATION	-23.95%	8.09B

Bio Therapeutic Drugs